Castle Biosciences' DecisionDx-Melanoma Test Enhances Risk Prediction for Melanoma Management

Enhancing Melanoma Care with DecisionDx®-Melanoma

Castle Biosciences, Inc. is set to present groundbreaking findings at the American Academy of Dermatology (AAD) Annual Meeting in 2026, specifically on DecisionDx-Melanoma, a gene expression profile (GEP) test that enhances risk prediction for patients with cutaneous melanoma. By leveraging data from the Surveillance, Epidemiology, and End Results (SEER) program, the new study highlights how this innovative test refines the understanding of mortality risk within various stages of melanoma as defined by the American Joint Committee on Cancer (AJCC).

In their analysis, researchers evaluated data from a cohort of 1,868 patients with AJCC stage I–III melanoma, revealing that DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival rates. This capability allows clinicians to distinguish between patients at high and low risk within the same AJCC stages, which could lead to more personalized and effective treatment plans.

Dr. Harrison Nguyen, the lead author of the study, stated, "The findings emphasize that traditional staging is insufficient on its own. By integrating DecisionDx-Melanoma into routine assessments, physicians gain additional biologic insights that enhance their ability to make informed decisions regarding patient management."

The results underscore how the DecisionDx-Melanoma test can clearly delineate patients whose risk levels are misplaced based on conventional staging methods. For example, patients with T1 tumors classified as high-risk (Class 2B) exhibit a five-year survival rate dropping to 70%, dramatically lower than the 96.7% reported for low-risk patients (Class 1A). This also extends to those with more advanced Stage IIB–III disease, wherein survival rates contrast starkly between high and low-risk categorizations at 48.5% and 87.4%, respectively.

DecisionDx-Melanoma gives healthcare providers the tools needed to prioritize care for individuals demonstrating a significant risk of poor outcomes while allowing for less intense management where appropriate. This proactive approach aligns with Castle Biosciences' mission to utilize rigorous science in patient assessments and treatment pathways.

During the AAD conference from March 27 to 31, 2026, detailed findings will be showcased in poster presentations, notably ePoster 76747, which presents an actionable framework for risk stratification linked to five-year melanoma-specific survival rates across AJCC subgroups.

The integration of DecisionDx-Melanoma into clinical practice is not merely an incremental enhancement; it is part of a commitment backed by over 50 peer-reviewed publications, clinical validation in over 10,000 patient samples, and a robust history of ordering and effective implementation. This makes it a crucial asset for clinicians navigating the complexities of melanoma management.

Ultimately, as melanoma continues to be a leading cause of skin cancer mortality, refining risk assessment strategies with tools like DecisionDx-Melanoma equips healthcare providers with critical insights to improve survival outcomes for patients. Castle Biosciences continues to lead in providing actionable genomic solutions that resonate with the evolving landscape of medical care and inform treatment decisions effectively.

For those attending AAD 2026, Castle Biosciences invites you to explore their innovative findings at booth #3345. More details about their ongoing research and the decision-making processes enabled by the DecisionDx-Melanoma test can also be found on their official website, encouraging a future where melanoma management is not only personalized but also rooted in cutting-edge science.